Brefeldin A

Catalog No.S7046

Brefeldin A  Chemical Structure

Molecular Weight(MW): 280.36

Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis. It could also improve the HDR(homology-directed repair) efficiency and be an enhancer of CRISPR-mediated HDR.

Size Price Stock Quantity  
In DMSO USD 80 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 14 Publications

3 Customer Reviews

  • Cells were treated with brefeldin A or manumycin A, and the resulting supernatant was collected after 48 h for exosomal preparation (lanes 1 and 2), or exosomes obtained from C81 cells were trypsin-treated or freeze/thawed (F/T) and then trypsin-treated (lanes 3 and 4). Lanes 5 and 6, input exosome controls from C81 or CEM cells, respectively. Resulting exosomes were assayed for the presence of Tax by Western blotting.

    J Biol Chem, 2014, 289(32):22284-305.. Brefeldin A purchased from Selleck.

  • Immunofluorescence staining of LC3 protein expression of U2OS cells treated with DMSO (negative control), Rap (positive control, 500 nM), Tha (1 μM), Tun (2 μg/mL), BFA (10 μg/mL), and DTT (4 mM) for 8 h. Immunoblot of ER-phagy-related proteins of U2OS cells treated with four ER stress inducers.

    Nanoscale, 2018, 10(18):8796-8805. Brefeldin A purchased from Selleck.

  • CSFV proliferation in ST cells with or without BFA was observed by IFA at 24, 48 and 72 hpi.

    J Biosci, 2018, 42(1):43-56. Brefeldin A purchased from Selleck.

Purity & Quality Control

Choose Selective ATPase Inhibitors

Biological Activity

Description Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis. It could also improve the HDR(homology-directed repair) efficiency and be an enhancer of CRISPR-mediated HDR.
Targets
ATPase (HCT 116) [1]
0.2 μM
In vitro

Brefeldin A is a fungal metabolite and blocks the forward transport between the endoplasmic reticulum and Golgi apparatus, Brefeldin A causes an impaired distribution of the membrane proteins. When HCT 116 human colon cancer cell is treated with Brefeldin A, morphological changes indicating cell differentiation are observed. Brefeldin A exerts its cytotoxic effects mainly by inducing differentiation and apoptosis in tumor cells. [1] The treatment of the strips with 20 μg/mL Brefeldin A for 6 hours completely abolishes the relaxation induced by bradykinin in the presence of 10mM indomethacin and 30 μM L-NOARG. The treatment with 20 μg/mL Brefeldin A substantially abolishes the bradykinin-induced decreases in [Ca2+]i and tension in the range of concentrations between 1 nM and 1 mM. Brefeldin A has no effect on the [Ca2+]i elevation in endothelial cells induced by bradykinin or substance P. [2] Addition of the fungal metabolite Brefeldin A does not affect the spontaneous phospholipid-dependent GTPS binding to myr-rARF1 but totally abolishs the retinal isotonic extract (RIE)-catalyzed exchange, with half-maximal inhibition at 2 μM Brefeldin A. Brefeldin A prevents a wide variety of membrane traffic pathways. Brefeldin A inhibits an ADP-ribosylation factor-specific guanine nucleotide exchange activity present in Golgi membranes or in brain cytosol. The complete prevention by Brefeldin A strongly suggests that the retinal extract contains an ARF-specific guanine nucleotide exchange factor. Retinal isotonic extract (RIE)-catalyzed GTPS release from both ADP-ribosylation factors (ARFs) is only partly inhibited by Brefeldin A, even at 300 μM. [3] Brefeldin A induces fusion of the Golgi apparatus with the ER. Brefeldin A abolishes the inhibitory effect of the CERT inhibitor HPA-12. Brefeldin A treatment, which induces fusion of the Golgi apparatus and the ER, rescues the limonoid-induced prevention of sphingomyelin biosynthesis. BFA treatment of CHO cells causes a 2 to 3 fold increase in sphingomyelin synthesis. [4] Apart from B-CLL cells, Brefeldin A reportedly causes apoptosis in multiple myeloma (U266, NCI-H929), Jurkat, HeLa, leukaemia (HL60, K562, BJAB), colon (HT-29) and prostate, as well as adenoid cystic sarcoma cells. The administration of 25 ng/mL of Brefeldin A completely blocks growth of HF4.9 and HF28RA cells, whereas higher Brefeldin A doses (75 ng/mL) are required to achieve the same effect in HF1A3 cells. Cell proliferation is inhibited within 24 hours in a dose-dependent manner and, depending on the cell line, almost complete cessation of 3H-thymdine incorporation is observed at 50-75 ng/mL of Brefeldin A (26%, 76%, 87% inhibition at 50 ng/ml and 75%, 87%, 92% inhibition at 75 ng/mL for HF1A3, HF4.9 and HF28RA cells respectively. Brefeldin A-induced cell killing is in a dose-dependent manner using YO-PRO 1/PI assay. [5] Brefeldin A could improve the HDR(homology-directed repair) efficiency. It is an enhancer of CRISPR-mediated HDR[6].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PC12 NGLUNHFHfW6ldHnvckBCe3OjeR?= M2LHeVIh|ryP MWKxJIg> NEnrTItqdmirYnn0d{B1cGViTD3EU3BCKCh{MNMg{txOMS2rbnT1Z4VlKHS{YX7zbYVvfCCHUluxM|IheGixc4Doc5J6dGG2aX;uxsA> MknqNlY{PjNzOUG=
C2C12 M2LiemZ2dmO2aX;uJGF{e2G7 NGPacmQyyqEQvHevcYw> M1:3[FHDqGh? NXPI[JZq[WKxbHnzbIV{KGO7dH;rbY5mKHKnbHXhd4Uh\nKxbTDDNmMyOiCveX;0eYJmew>? NEjTWowzPjJ7MUK3PS=>
MEFs WT MkLFSpVv[3Srb36gRZN{[Xl? M2Dpd|XDqM7:TR?= NFKxd3kzOCCvaX6= M123[YNifXOnczDy[ZNq\GWwdDDlcpp6dWW|IIP1Z4gh[XNiTlHHWE1ITlBuIITvJIRq\m[3c3WgZoFkcyC2bzD0bIUhTVJ? M3rIdFI3OTl4MEKz
MEFs VAMP7 KO M4e2VWZ2dmO2aX;uJGF{e2G7 NXm5THFyPcLizszN NFzFXFMzOCCvaX6= MULjZZV{\XNicnXzbYRmdnRiZX76fY1meyC|dXPoJIF{KE6DR2StS2ZRNCC2bzDkbYZnfXOnIHLhZ4shfG9idHjlJGVT MXqyOlE6PjB{Mx?=
SMCs Mmi1SpVv[3Srb36gRZN{[Xl? MY[xNOKhyrWpL33s MnLwNE0yOiCq MnntSG1UVw>? NF3LcHN{cG:5czDhJJRz\W6mIITve4Fz\HNiYTDobYdp\XJiY3;uZ4VvfHKjdHnvckBw\iC2aHWgSXIwW1JibnX0e49zcyCrbjD0bIUheGW{aX71Z4xm[XJiYYLlZeKh MXWyOlE4OjB6MB?=
SMCs NHfqfJVHfW6ldHnvckBCe3OjeR?= NGHYOJQyOMLiwsXnM41t MVWwMVEzKGh? MlizSG1UVw>? M{XJUYNifXOnczDhJJRz[W6|aXXueEBE[TJtwrDy[Yxm[XOnIH\yc40hfGinIFXSM3NTyqB? MVWyOlE4OjB6MB?=
HEMC-1 NG\HV4hHfW6ldHnvckBCe3OjeR?= NIjDUYcxNjIEoNM1[{9udA>? M3n6eVI1yqCq NXLvZVF[[2G3c3XzJIEhcGmpaHXyJIlvcGmkaYTvdpkh\W[oZXP0JI9vKGW6b3P5eI9{cXNidHjhckBvd2OxZHH6c4xm NFH2SmQzPTl5Mke1PS=>
HUVEC MoHySpVv[3Srb36gRZN{[Xl? M4K2W|ExyqEQvF2= MVWxxsBp M2m2U2ROW09? NFPJN3Ni[m:uaYPo[ZMhcHmyb4jpZU1qdmS3Y3XkJJJmdGWjc3Wgc4YhSVSSIH\yc40h[XCrY3HsJIFv\CCkYYPvcIF1\XKjbDDzeZJn[WOncx?= MkfONlU6PTZ7OEi=
HUVEC NWf2O4MyTnWwY4Tpc44hSXO|YYm= MnTLNVDDqM7:TR?= MmLiNeKhcA>? NGDHfHdFVVOR NVHER29GcW6lcnXhd4V{yqC2aHWgcpVu[mW{IHHu[EBqdnSnboPpeJkhd2ZiZnz1c5Jme2OnboSgZZJm[XNiZYPw[YNq[WyueTDpckBx\XKrboXjcIVieiC|cHHj[S=> Mn\QNlU6PTZ7OEi=
Caco-2 NEHPOYxHfW6ldHnvckBCe3OjeR?= NIGwUoczNjVizszN MYezNEBucW5? NIDiOVVifHSnboXheIV{KHSqZTDUS2Yu|rJzLX3l[IlifGWmIHnuZ5Jm[XOnIHnuJHNGWlRiZoXuZ5Rqd25? M1jZcFI2QTV2OUOx
NRK NYfqcGVCTnWwY4Tpc44hSXO|YYm= MUeyNFDjiIWwZz;tcC=> NGP6O|E16oDHaB?= NHHUXlVFVVOR NVLtbmZZemW|Y4Xld{BucXSxdHnjJJBzd2e{ZYPzbY9v Mo\4NlU6PDh3OE[=
HeLa MULGeY5kfGmxbjDBd5NigQ>? MViyNFDjiIWwZz;tcC=> MonTN{Bp NXPydpJlTE2VTx?= NVXJUIJwcW6mdXPld{B1cGViYYL0bYZq[2mjbDDidoVicy23cDDv[kB1cGViR3;s[4kh[2:vcHzlfC=> MknKNlU6PDh3OE[=
COS Mo[xSpVv[3Srb36gRZN{[Xl? MVexJO69\y:vbB?= NVXKdZM2OyCq NFH5UYFkd22ybHX0[Yx6KGSrc4DldpNmeyC2aHWgRXAuOSC|aXfuZYzDqA>? MXKyOVkyPTlyMB?=
DF1  Mn23SpVv[3Srb36gRZN{[Xl? M{nKS|HDqM7:TdMg MYe0PEBp NVv6dIVETE2VTx?= MnLX[Il{eGW{c3XzxsB1cGViZYjv[4Vvd3W|IFPTS4FtVkGlVEKgdJJwfGWrbh?= NH7H[o0zPThyN{C1OC=>
nHDFs  M4W0OmZ2dmO2aX;uJGF{e2G7 M3HUSVHDqM7:TdMg M3PkOVLDqGh? MX;wdoV3\W62czD0bIUh[XO|ZX3icJkhd2ZiY4n0c5NwdGmlIHPvZZQheHKxdHXpcpMhd262bzDHc4xocSCvZX3idoFv\XN? MWWyOVc4OjZzNh?=
FRT  M164eWZ2dmO2aX;uJGF{e2G7 NHrsWnI2KM7:Zz;tcC=> MVmyxsBp MmCyZoxw[2u|IITyZYZncWOtaX7nJJRpem:3Z3igeIhmKEexbHfpJINwdXCuZYigZpkhcW6qaXLpeIlv\yCHUj30c{1Id2ypaTD0doFve3CxcoS= MmLONlU4PjdzMUW=
FRT  M3SzcWZ2dmO2aX;uJGF{e2G7 NX;kPI05PSEQvHevcYw> NXHkcHoxOsLiaB?= MnzGdJJmfmWwdIOgeIhmKGmwY4LlZZNmKGmwIHPs[YF3\WRizsGgd5VjfW6rdIOge4hmdiCdTnGrYYnDqHejczDy[YR2[2Wm M{H5NFI2PzZ5MUG1
HepG2  NVvrRmRzTnWwY4Tpc44hSXO|YYm= MkDqNgKBkcL3TdMg NV3mNHZZOjRiaB?= NHfSWGtFVVOR NFT6dXVl\WO{ZXHz[ZMhfGinIHzleoVtKG:oIGDYVkBuWk6D MnTmNlU3OTZ3OUe=
SMCs NWDwcIR[TnWwY4Tpc44hSXO|YYm= MlyxNe69\y:vTB?= NED6bnU{KGh? MlP0ZYNkfW23bHH0[ZMhS06SWUKgdJJwfGWrbjDpckB1cGViRWKgZ49ueGG{dH3lcpQh[W6mIH7vJIxwdmencjDjc{1td2OjbHn6[YQhf2m2aDD0bIUhT2:uZ3mgcYFzc2W{wrC= MV[yOVU5QTR{NR?=
OB-6 Mo\jRZBweHSxc3nzJGF{e2G7 NYPSVWg6Oi55wrFOwG0> MoTSOFghcA>? MkPCbY5lfWOnczDhdI9xfG:|aYO= NES5XVUzPTV|MkS4NC=>
iPSC-CMs  MorMSpVv[3Srb36gRZN{[Xl? NGHxVZo2ODBibnevcYw> NXezcFFYPDhiaB?= M171Volv[3KnYYPld{B1cGViaX70[Y5{cXS7IH;mJJRp\SCqaXfo[ZIhdW:kaXzpeJkhVEGPUIOgZZQhfGinIHPvd5Qhd2ZidHjlJIxwf2W{IH3vZoltcXS7IIPw[YNq\XN? NWLwN2E{OjV2OEi2OlY>
SP-Nluc MmrRSpVv[3Srb36gRZN{[Xl? M4rydFUhdWdxbVy= MWO2JIg> Mnr0SG1UV8Li MoPnZ4F2e2W|IHHuJIlv[3KnYYPlJIlvKHKncH;yeIVzKGGldHn2bZR6KGmwIITo[UBx[XKjc3n0[S=> NHvxVowzPTN7Mkm5PC=>
PEXEL-Nluc MoHUSpVv[3Srb36gRZN{[Xl? M1;LSVUhdWdxbVy= MXu2JIg> NX70TVJiTE2VT9Mg NEnPeYlk[XW|ZYOgZY4hcW6lcnXhd4UhcW5icnXwc5J1\XJiYXP0bZZqfHliaX6geIhmKHCjcnHzbZRm NH\jOZczPTN7Mkm5PC=>
H1299 NGfje2NHfW6ldHnvckBCe3OjeR?= NFz6RpEyOCEQvHevcYw> NF24UFMzPCCq MVXpcoR2[2W|IHH1eI9xcGGpedMg MVGyOVM5QDl5MB?=
MDA-MB-231 NXOycpplS2WubDDWbYFjcWyrdImgRZN{[Xl? MWCw5qCUPTBizsznM41N MYS0PEBp NHjaRoVGSzVywrC9JFAvODF4INM1[{9uVA>? NF7HVVAzPTN3NkW2Oy=>
MDA-MB-231 MVnBdI9xfG:|aYOgRZN{[Xl? M2Hs[VAvOSEQvHevcWw> MkLDOEBp NUHjeHd4cW6mdXPld{BieG:ydH;zbZM> NI\UemIzPTN3NkW2Oy=>
MDA-MB-231 M2excGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfYNE4xOS9yLkC1JO69\y:vTB?= MUSyOEBp MoTUbY5kemWjc3XzJJRp\SCocnHjeIlwdiCxZjDzeYIuTzFiY3XscEBl\WK{aYO= NX\ifVRnOjV|NU[1Olc>
MDA-MB-231 MnnFRZBweHSxc3nzJGF{e2G7 NVHMfYxYOC5yNfMAl|Eh|rypL33M M3LseFI1KGh? MX\pcoR2[2W|IGDBVnAhMHCxbImgRWRRNXKrYn;z[UBxd2y7bXXyZZNmNTFrIHPs[YF3[Wen NIG0R48zPTN3NkW2Oy=>
MDA-MB-231 NFjXTZZHfW6ldHnvckBCe3OjeR?= M3PlSFDjiJN3MDFOwIcwdUx? M3HybVI1KGh? M{XwO4lvcGmkaYTzJJRp\SCob4LtZZRqd25ib3[gN2Qh[W6mIELEJINwdG:waXXz MYCyOVM2PjV4Nx?=
A172 Mk\WSpVv[3Srb36gRZN{[Xl? NH3XZocyOMLizsznM41t MWS0xsBp MlK0SG1UV8Li MnL6doV{fWy2czDpckB1cGVicnX0do9oemGmZTD0doFve3CxcoSgc4Yh\my3b4Lld4NmdnRiZ4LhcpVt\XN? NESzSW8zPTJ|OUWwOy=>
KMS-6 MmTYSpVv[3Srb36gRZN{[Xl? NEHSXFcyyqEQvF5CpC=> MknQNlQhcA>? Mki5[ZhpcWKrdIOgbIFt\iC2aHWgd4VkemW2aX;uJI9nKGejbHHubY4uVEliYYOg[IllKHSqZTDjc451em:u MnLmNlUzOjlzMk[=
MEC NYj1RVNGTnWwY4Tpc44hSXO|YYm= NF7tPZYyKM7:TR?= M4ToV|EvPSCq NXPmTmFV[2G3c3XzJIEh\HKjbXH0bYMh\GWlcnXhd4UhcW5idHjlJJN2em[jY3WgWmVITlJ{ M1;tTFI2OjJ6OEG1
HEK293/hERG MYHGeY5kfGmxbjDBd5NigQ>? MYexNOKh|ryP MmTJNeKhcA>? M3L1WJJme3WudIOgbY4h[SC2aX3lMYRmeGWwZHXueEBz\WS3Y4Tpc44hdWG2dYLlJIhGWkdicILveIVqdsLi NI\1bm0zPTJzOES2PS=>
RBE4 NX;RRnd[SXCxcITvd4l{KEG|c3H5 MUCyxsDPxE1? MYKz5qCUOjUEoHi= NGLO[pFqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nIHTldIVv\GWwdHz5 MXWyOVEzQDB{NR?=
RBE4 MYnGeY5kfGmxbjDBd5NigQ>? NEHTW24zyqEQvF2= NXv2XZBxO+LCk{K0xsBp MkPWbY5kemWjc3XzJJRp\SC[QmCxJJBzd3SnaX6gcIV3\Wy|IHHmeIVzKDNiYX7kJFbDqGhib3[geJJm[XSvZX70 NEfxZlUzPTF{OECyOS=>
RBE4 M4rLN2Z2dmO2aX;uJGF{e2G7 M1zGN|LDqM7:TR?= NWTZVZdlO+LCk{K0xsBp M4T0WIlv[3KnYYPld{Bi[3SrdnWgZ4F{eGG|ZT2xNkBqdiCjIITpcYUu\GWyZX7k[Y51KG2jbn7lduKh MoLvNlUyOjhyMkW=
RBE4 MkTGSpVv[3Srb36gRZN{[Xl? MWqyxsDPxE1? MWez5qCUOjUEoHi= NYXaUFB{cW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[gVm9UKHSrbXWt[IVx\W6mZX70cJk> M2TpXVI2OTJ6MEK1
RBE4 NVHoXJJsTnWwY4Tpc44hSXO|YYm= MVGyxsDPxE1? M{\EcFPjiJN{NNMgbC=> NE\jOpZqdmS3Y3XzJIEh\GWuYYnl[EBl\XCuZYTpc44hd2ZidHjlJGVTKEOjMjxCpINwdnSnboSgZZQhPsLiaDDv[kBqdmO3YnH0bY9vKHOrZ37p[olk[W62bIm= MkSxNlUyOjhyMkW=
RBE4 MXnGeY5kfGmxbjDBd5NigQ>? MmXrNuKh|ryP MmHmN-KBmzJ2wrDo M4i3eolv\HWlZYOgZY4hd3[ncnzvZYQhd2ZiQ3GyL:KhcW5idHjlJI1qfG:laH;u[JJq[SCrbjD0bIUh\mm{c4SgOuKhcCCxZjDpcoN2[mG2aX;uJEhx6oDLPPMAjVAvODBzKTDieZQhS2F{K9MgcIV3\Wy|IHnuJJRpcXNib4LnZY5mdGynIHTlZ5Jm[XOnZDDh[pRmeiBzMtMgbEBw\iCrbnP1ZoF1cW:w NFKwR2czPTF{OECyOS=>
Huh-7  NVrsdpg3TnWwY4Tpc44hSXO|YYm= NF6xfVIy|rypL33M NX\zUmFHO+LCk{K0xsBp NHP3WZRqdmO{ZXHz[ZMhfGinIHzleoVtKG:oIFHQSVEhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> Ml7DNlUxOjZzN{S=
HepG2  NVHufnlYTnWwY4Tpc44hSXO|YYm= NXnHVog1Oc7:Zz;tUC=> MV[z5qCUOjUEoHi= MVrpcoNz\WG|ZYOgeIhmKGyndnXsJI9nKEGSRUGgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NYjFSFZJOjVyMk[xO|Q>
H838-LKB1 M37Kc2Z2dmO2aX;uJGF{e2G7 NFXHVVE{OMLibnevcYw> M3TsOVEzNzF6IHi= NHLQNZNqdmO{ZXHz[ZMhfGinIIDyc5RmcW5ibHX2[Yx{KG:oIFLpVOKh NH35dnkzPTBzMUC4Ni=>
H838-KDLKB1  NVnpfFJQTnWwY4Tpc44hSXO|YYm= MVizNOKhdmdxbXy= NWX6dVBkOTJxMUigbC=> NEPvNlhqdmO{ZXHz[ZMhfGinIIDyc5RmcW5ibHX2[Yx{KG:oIFLpVOKh MVSyOVAyOTB6Mh?=
H838-KDLKB1  NVrFbnZXTnWwY4Tpc44hSXO|YYm= NFrSVIs{OMLibnevcYw> MXKxNk8yQCCq NX71S2VWcW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[gdIhwe3Cqb4L5cIF1\WRiZVnGNu6yKCiyaH;zdIhwNWWLRkNOtUk> M4WwWVI2ODFzMEiy
3T3-L1 MUHGeY5kfGmxbjDBd5NigQ>? M{Hu[FUh|rypL33s NEKzNIQ{OCCvaX6= NWHodVdOdWmvaXPzJJRp\SCnZn\lZ5R{KG:oIHnud5VtcW5iYX7kJINifXOnczDyc4J2e3RicHjvd5Bpd3K7bHH0bY9vKG:oIFHreEApW2W{IES3N{kh[W6mIIDoc5NxcG:{eXzheIlwdiCxZjDBV|E3OCBqVHjyJFY1OiCjbnSgV4VzKDV6ODm= MoDuNlQ5PDN6Mke=
3T3-L1 NWn0VIpQTnWwY4Tpc44hSXO|YYm= NUHEWYU5PSEQvHevcYw> MmTiN|AhdWmw MX3y[YNieGm2dXzheIV{KGmwc4XsbY4h[WO2aX;uJJdqfGhicnXzdIVkfCC2bzDy[Yd2dGG2aX7nJGFsfCCjY4Tpeol1gSCjbnSgRXMyPjBicHjvd5Bpd3K7bHH0bY9v NHewVpYzPDh2M{iyOy=>
3T3-L1 M2rHc2Z2dmO2aX;uJGF{e2G7 NE\BfFI2KM7:Zz;tcC=> NIPDc5Y{OCCvaX6= MlzXZ4F2e2W|IILleoVze2mkbHWgdoVlcXO2cnnieZRqd25ib3[gS2xWXDR? MYmyOFg1Ozh{Nx?=
3T3-L1 MoW1SpVv[3Srb36gRZN{[Xl? MUi1JO69\y:vbB?= NYrFbGNDOcLiaB?= M3rj[INifXOnczDy[YRqe3S{aXL1eIlwdiCxZjDHUHVVPCCkdYSgco91KGmwY4LlZZNmKGmwIHfseYNwe2VidYD0ZYtm NH\Fem4zPDh2M{iyOy=>
3T3-L1 M1jQSWZ2dmO2aX;uJGF{e2G7 NFzhdYU2KM7:Zz;tcC=> NGT6bZEyyqCq MlTxZ4F2e2W|IIDoc5NxcG:{eXzheIlwdiCxZjD0bIUhTm:6T{GgeJJidnOlcnnweIlwdiCoYXP0c5I> NILZXHMzPDh2M{iyOy=>
HeLa  M4HUT2Z2dmO2aX;uJGF{e2G7 NGDWc3M2KM7:Zz;tcC=> MkO4N{Bp Mlj6Z4F2e2W|IH71Z4xm[XJiZYjjcJV{cW:wIH;mJJRp\SCIb4jPNUB1emGwc3PybZB1cW:wIH\hZ5RweiCjbnSg[IVkemWjc3XzJJRz[W6|Y4LpdJRqd25ib3[gSo95VzFvcnXneYxifGWmIHflcoV{ NEPJPZYzPDh2M{iyOy=>
HEK293 MlOzSpVv[3Srb36gRZN{[Xl? NYHIZXZHPcLizsznM41t MmfXNVLDqGh? MUHhZo9tcXOqZYOgR21CNWmwZIXj[YQhS1KHTFSyJJNm[3KndHnvci=> MofrNlQ3QDd2M{G=
COS-1 NUHBSXo{TnWwY4Tpc44hSXO|YYm= NEPxSXk2KML3Zz;tcC=> MnvuNlQhcMLi NUXwVlVEemW|dILpZ5R{KGyxY3HsbZpifGmxbjDv[kBPSiCrbjD0bIUheGW{aX71Z4xm[XJicnXnbY9vyqB? M332cFI1PjdzN{Wx
PRP MVXGeY5kfGmxbjDBd5NigQ>? NFPkflgyOCEQvF2= NVvIdGJE[WK{b3fheIV{KFOGRj2x{tEudWWmaXH0[YQhS1iFUkeg[Zh1\XKwYXzpfoF1cW:wwrC= NVzjS3dQOjR4Nki3OVA>
RAW264.7 MV7BdI9xfG:|aYOgRZN{[Xl? M1zXVlQh|ryP M2\Tc|Q5KGh? MnnjZZR1\W63YYTld{B1cGViaX7obYJqfGmxbjDv[kBwgC2ORFytbY5lfWOnZDDhdI9xfG:|aYOgZY5lKHSqZTDmZYNqdGm2YYTpc44hd2ZiY3jvcIV{fGW{b3yg[YZndHW6IHL5JGFkNWiHLUG4RU1PUDJ? NGL5TG8zPDZ|OUCzNi=>
MDMs NH7rd3dCeG:ydH;zbZMhSXO|YYm= NHToeYEyOOLCid88[{9udA>? MnzlNVIwOTViaB?= NVizPHI5cW6mdXPld{BieG:ydH;zbZM> NYnzN3RiOjR3NU[2PVU>
PMHs  M3r1dWZ2dmO2aX;uJGF{e2G7 MUOxNQKBmzJy4pEJ{txoN22u MnPiNlTjiImq MYrEUXNQ M{\BU4lv\HWlZXSgSXIhe3S{ZYPz NVrlPW5EOjR2MEeyOFI>
PMHs  NX3ycGxNSXCxcITvd4l{KEG|c3H5 M2fkVlEx6oDVMkFihKnPxGdxbXy= MlLVNlTjiImq NEXmbWZFVVOR M1vBNIlv[3KnYYPld{Bk\WyuIHTlZZRp NFTiV3gzPDRyN{K0Ni=>
HEK293/tau NWSwZYFzTnWwY4Tpc44hSXO|YYm= M4LDb|Uh|ryP NYnEZ2lCOS9{L{SgbC=> MnW4bY5lfWOnczDHc4xocSCocnHncYVvfGG2aX;uxsA> M3LXd|I1OzZ6MEi5
HEK293/tau MmXKSpVv[3Srb36gRZN{[Xl? NWnwSXg3PSEQvF2= M1\JNVMhcA>? NVvneoxFcW6mdXPld{B1[XViaInw[ZJxcG:|cHjvdplt[XSrb36= NX;YPVBsOjR|NkiwPFk>
ADF MkHSSpVv[3Srb36gRZN{[Xl? MnrJNVAh|ryP MV[xOkBp MmThbY5pcWKrdIOgeIhmKFqwQ3yyMYlv\HWlZXSgeJJidnOub3PheIlwdiCxZjDDVnQ> MVmyOFIzQDJ|Mh?=
U373  NIPPeFhHfW6ldHnvckBCe3OjeR?= NUPPc|RuOTBizszN MlzXNVYhcA>? M{TYSIlvcGmkaYTzJJRp\SCcblPsNk1qdmS3Y3XkJJRz[W6|bH;jZZRqd25ib3[gR3JV NV62TpdHOjR{MkiyN|I>
RKO-HIPK2i MVrGeY5kfGmxbjDBd5NigQ>? NGHFcGEyOCEQvF2= MlPMNVYhcA>? MlHObY5pcWKrdIOgeIhmKFqwQ3yyMYlv\HWlZXSgeJJidnOub3PheIlwdiCxZjDDVnQ> NFvuVJMzPDJ{OEKzNi=>
ADF  Ml[zSpVv[3Srb36gRZN{[Xl? MXuxNEDPxE4EoB?= MW[2JIg> M{L4SolueGGrcoOgeIhmKESFIHHjeIl3[XSrb36= MVmyOFIzQDJ|Mh?=
Huh7 MnPNSpVv[3Srb36gRZN{[Xl? NFfzXJM2KM7:Zz;tcC=> M4\2NVQhcA>? M2jlWoFjd2yrc3jld{B1cGVic3XjdoV1cW:wIH;mJEBqdnS{YXPlcIx2dGG{IFHwc2I> NWnvRpdGOjRzMECxOFA>
Huh7 MYnGeY5kfGmxbjDBd5NigQ>? M13LXlUh|rypL33s M4OyTFEhcA>? MoTRZ4F2e2W|IHGgd4lodmmoaXPhcpQhcW6lcnXhd4UhcW5iQYDvRk1kemW|Y3XueJM> M4TXOlI1OTByMUSw
Huh7 MkHQSpVv[3Srb36gRZN{[Xl? M1;sb|XjiJNzMNMgcocwdWx? M4exW|EzKGh? MnTDbY5kemWjc3XzJGFxd0JvY4Lld4NmdnS|IIfpeIhwfXRiaX7obYJqfGmwZzDz[YNz\XSrb36= Mlq1NlQyODBzNEC=
BAECs NX;qdWRkTnWwY4Tpc44hSXO|YYm= MmKzOUDPxGdxbXy= NEj1OG4xNTRiaB?= M2XpTYlv\HWlZYOgeIhmKHKjcHnkJIRmeGixc4Doc5J6dGG2aX;uJI9nKGWQT2OgZZQhW2W{MUG3PS=> MYiyOFA5PTJ{NR?=
Macrophages M4PqS2Z2dmO2aX;uJGF{e2G7 NYDFWo9WPzFiwsXN NVv0RWM2PiCq M4nHR4lvcGmkaYTzJIx2dmG|aX6gbY51\XKwYXzpfoF1cW:wwrC= NXTiN3JtOjRyM{m3OFA>
Colo 205 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\GNlRIOC13IN88[{9uVA>? M4fCbVQ5KGh? MmnZbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5ic4XzdIVve2mxbjDjeYx1fXKnczD3bZRpKGGwIHXzeIlu[XSnZDDJR|UxKG:oII6xOUBv\y:vTB?= NWLKPFROOjN7N{O5PVY>
Colo 205 MmnGSpVv[3Srb36gRZN{[Xl? NXSzfoNmOC5yMUKtNE4xOjVizsznM41N Mn;qNVQh\A>? NGD2[2lz\WS3Y3XzJJRp\SClbH;uc4dmdmmlaYT5JI9nKEOxbH:gNlA2KEOVQ4O= NIDscpYzOzl5M{m5Oi=>
Colo 205 MoXLRZBweHSxc3nzJGF{e2G7 Mn7aNE4yKM7:Zz;tUC=> M3fad|AuOjRiaB?= MlrubY5lfWOnczDhdI9xfG:|aYOgc4YhS2:ubzCyNFUh[2WubIOgbY4he3W|cHXud4lwdiCldXz0eZJmew>? NHrOWo8zOzl5M{m5Oi=>
Colo 205 NVHKbW9lTnWwY4Tpc44hSXO|YYm= M33jd|AvODF3IN88[{9uVA>? Mn\NNlQhcA>? MXPpcoR2[2W|IITo[UBmgHC{ZYPzbY9vKG:oIFXSJJN1emW|cz3y[YxifGWmIHflcoV{ MYGyN|k4Ozl7Nh?=
Colo 205 MWPGeY5kfGmxbjDBd5NigQ>? NF20U5kxNjBzNTFOwIcwdUx? NV7FeXo{OjRiaB?= NWnzWmFycW6qaXLpeJMhfGinIHHjeIl3cXS7IH;mJG1OWHN? M{nRXlI{QTd|OUm2
IBRS2 M1OxOGZ2dmO2aX;uJGF{e2G7 MX:1JO69\y:vbB?= NIPwZ5kxNjViaB?= NUnWRXZoTE2VTx?= MWDkbZNzfXC2czD0bIUhTVKJSVOgZY5lKEexbHfpxsA> NX7SSGV5OjN7NkO1N|Q>
IBRS2 M1rtU2Z2dmO2aX;uJGF{e2G7 M13tXlUh|rypL33s NWrnUGJ3OC53IHi= NULHO2FoTE2VTx?= NXHmbWt[\W6qYX7j[ZMhTk2GVjDpcoZm[3Srb36= MYiyN|k3OzV|NB?=
HeLa MnXqSpVv[3Srb36gRZN{[Xl? MUOyJO69VQ>? MlTINkBpyqB? NV7IRopX[XS2ZX71ZZRmeyC2aHWgWG5HNWmwZIXj[YQhe2WlcnX0bY9vKG:oIFnMMVE2 M4jPfVI{QTVyOEmy
HFS  NGHESFJHfW6ldHnvckBCe3OjeR?= NVf0U|Q2OC1zIN88[{9udA>? Moq0NlQhcA>? MYLHUHRRKGW6cILld5Nqd25icnXhZ4hmeyCjIIDsZZRm[XViYYSgZ49v[2WwdILheIlwdnNiYYOgcI94KGG|IECuNFEhyrWpL33s Ml;zNlM5QTR4M{O=
HFS  NFS3c5pHfW6ldHnvckBCe3OjeR?= NWPTdHJnOC5yMTFCuYcwdWx? NXXqfmw1OjRiaB?= MVnpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[g[4x6[2:|cHjpcodwdGmyaXSgd5lvfGijc3Wg[4Vv\XNiYYSgOkBp NWXuUIVVOjN6OUS2N|M>
OVCAR-3 MoixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjYcoMy6oDVMUZCpO69VcLi MlPUNlTDqGh? MUjpcoR2[2W|IHGgcI9{eyCxZjDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6yqB? M1f3SlI{QDJ4OU[0
OVCAR-3 NW\4PYdkTnWwY4Tpc44hSXO|YYm= NEe2SWwy6oDVMUZCpO69VcLi MUGyOOKhcA>? MYnpcoR2[2W|IH71Z4xm[XJiZHHtZYdm MkK1NlM5OjZ7NkS=
OVCAR-3 MUXBdI9xfG:|aYOgRZN{[Xl? M3XWOFEuOTEEoN88US=> NHTIOGc1KGh? NF;z[29qdmS3Y3XzJJRp\SCjY4TpeoF1cW:wIH;mJIFxd3C2b4Ppd{1z\WyjdHXkJJBzd3SnaX7z NYq1U25oOjN6Mk[5OlQ>
OVCAR-3 NYraSlJRSXCxcITvd4l{KEG|c3H5 NUTIWIxpOTEEoN88US=> NFLISGczPMLiaB?= NV;4WWFOcW6mdXPld{Bi[3SrdnH0bY9vKG:oIHPhd5Bie2W| M3WxXVI{QDJ4OU[0
OVCAR-3 MYfGeY5kfGmxbjDBd5NigQ>? NGnMV48y6oDVMUFCpO69VQ>? NETVUGMzPMLiaB?= MlTGbY5lfWOnczDkbZNzfXC2aX;uJI9nKHSqZTDtbZRw[2ixbnTybYFtKHS{YX7zcYVu[nKjbnWgdI91\W62aXHs NWXzSWJ7OjN6Mk[5OlQ>
OVCAR-3 M13HUGZ2dmO2aX;uJGF{e2G7 NHvuV3Qy6oDVMUFCpO69VQ>? MVWyOOKhcA>? MXfpcoR2[2W|IH\vdo1ifGmxbjDv[kBz\WGldHn2[UBwgHmpZX6gd5Bm[2mncx?= NGHvd3EzOzh{Nkm2OC=>
OVCAR-3 M4jXdWZ2dmO2aX;uJGF{e2G7 NFLtVHgy6oDVMUFCpO69VQ>? NVu1dZZ5OjUEoHi= MVHpcohq[mm2czDj[YxtKGGmaHXzbY9vKGGwZDDtbYdz[XSrb36= NYrhNlNROjN6Mk[5OlQ>
MKN45 M{T3UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV:0bZU3UUN3MEywMlAxOSEQvHevcYw> M2fLN|I{Pzl|M{Sy
LOVO NWnuNVFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{H5XmlEPTB;MD6xNkDPxGdxbXy= NGLDVmMzOzd7M{O0Ni=>
A549 NYiwZYVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTBwMESg{txoN22u MoWwNlM4QTN|NEK=
MDA-MB-435 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXiTWM2ODxyLkCwNUDPxGdxbXy= Ml2wNlM4QTN|NEK=
HepG2 MlfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmT4TWM2ODxyLkCwNUDPxGdxbXy= NHnufYszOzd7M{O0Ni=>
HL-60 M4fUfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LOSGlEPTB:MD6wNFEh|rypL33s NFfsTJczOzd7M{O0Ni=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p53 / GRP78 ; 

PubMed: 22859938     


(B) present the dose- and time- dependent effect of ER stress inducer brefeldin A on p53 expression. MCF-7 Cells were exposed to brefeldin A in 10% FBS–supplemented DMEM as time and dose indicated. The cell lysates were analyzed by western blotting with antibodies for p53, GRP78, and α-tubulin. The p53 protein expression level was quantified densitometrically. GRP78 served as an ER stress marker. 

22859938
Immunofluorescence
MTP / GBF1 ; 

PubMed: 26267806     


3T3-L1 cells, plated as above, were treated with brefeldin A (5 μg/ml, 3 hr), fixed and stained for MTP and GBF1. Brefeldin A treatment leads to redistribution of MTP from the juxtanuclear region, similar to what occurs with GBF1. Bars = 10 μm.

ErbB3 / Calnexin ; 

PubMed: 21576364     


293T cells transfected with ErbB3 were treated without (top) or with (bottom) BfA, and confocal immunofluorescence microscopy was used to examine the colocalization of ErbB3 with endogenous calnexin.

FMNL1 / GM130 ; 

PubMed: 21868368     


FMNL1 colocalizes with the cis-Golgi marker GM130 and is dispersed by treatment with brefeldin A (+BFA).

26267806 21576364 21868368
Growth inhibition assay
Cell viability; 

PubMed: 28462831     


Effects of brefeldin A on human prostate cancer cells. LNCaP and PC-3 cells were seeded in cell culture dishes and incubated for 24 h. The cells were then treated with different concentrations of brefeldin A for 72 h. The number of viable cells was determined by the trypan blue exclusion assay. Apoptosis was determined by propidium iodide staining and morphological assessment.

28462831

Protocol

Cell Research:

[5]

+ Expand
  • Cell lines: Human follicular lymphoma cell lines HF1A3, HF4.9 and HF28RA
  • Concentrations: 0 ng/mL -75 ng/mL
  • Incubation Time: 5 days
  • Method:

    HF1A3, HF4.9 cell viability upon the treatments is tested using double staining of cells with YO-PRO 1/PI and SYTO16/PI probes. To access cell proliferation, cells are treated with 0–100 ng/mL Brefeldin A in complete medium for 20 hours before adding 1 μCi/mL [methyl-3H]-thymidine for additional 4 hours at 37 °C. The incorporated radioactive thymidine is quantified by scintillation counting with Microbeta counter. To examine long-term effects of Brefeldin A treatment, cells are seeded at initial concentration 105 cells/mL and treated with 0-75 ng/mL Brefeldin A for up to 5 days. At the time indicated, a sample of cells is removed and viable cell number is assessed by standard Trypan Blue exclusion assay.


    (Only for Reference)

Solubility (25°C)

In vitro DMSO 4 mg/mL (14.26 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 280.36
Formula

C16H24O4

CAS No. 20350-15-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ATPase Signaling Pathway Map

Related ATPase Products

Tags: buy Brefeldin A | Brefeldin A supplier | purchase Brefeldin A | Brefeldin A cost | Brefeldin A manufacturer | order Brefeldin A | Brefeldin A distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID